Zaltrap
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
Zaltrap ‘no’ from NICE
June 21, 2013Sales and Marketing NICE, Sanofi, Zaltrap
NICE is preparing to discard Sanofi’s Zaltrap as an NHS option for treating metastatic colorectal cancer (mCRC) that is resistant …
Zaltrap launched in UK
March 4, 2013Sales and Marketing Sanofi, Zaltrap
Sanofi and Regeneron Pharmaceuticals’ bowel cancer drug Zaltrap has been launched in the UK today. Zaltrap (aflibercept) will be used …
Sanofi ups stake in Regeneron
February 13, 2013Sales and Marketing AMD, Regeneron, Sanofi, Zaltrap
Sanofi is increasing its stake in Regeneron Pharmaceuticals by buying shares on the open market and from existing shareholders. The …
Sanofi celebrates EU approvals
February 5, 2013Sales and Marketing Lyxumia, Sanofi, Zaltrap, diabetes
Sanofi is celebrating after diabetes treatment Lyxumia (lixisenatide) and metastatic colorectal cancer (mCRC) drug Zaltrap received authorisation in Europe. The …
Sanofi’s Zaltrap data published
October 8, 2012Research and Development, Sales and Marketing Erbitux, Sanofi, Stivarga, Zaltrap, avastin
Detailed data from the Phase III trial of Sanofi’s newly-licenced anti-VEGF cancer drug Zaltrap, co-marketed with Regeneron, has been published. …
Regeneron to expand workforce at New York facility
August 8, 2012Manufacturing and Production Arcalyst, Eylea, Regeneron, Zaltrap
Buoyant product sales at US biotech Regeneron have prompted the company to undertake a recruitment drive at its manufacturing facility …
Sanofi’s colorectal cancer drug gains FDA approval
August 6, 2012Sales and Marketing FDA, Sanofi, Zaltrap, colorectal cancer
The FDA has approved Sanofi and Regeneron’s new oncology drug Zaltrap for aggressive forms of colorectal cancer.Zaltrap (ziv-aflibercept), in combination …
FDA grants priority review for Sanofi cancer drug
April 5, 2012Research and Development, Sales and Marketing Erbitux, FDA, Regeneron, Sanofi, Zaltrap, colorectal cancer, prostate cancer
The FDA has granted Sanofi and partner Regeneron priority review for their colorectal cancer drug Zaltrap. Zaltrap (aflibercept) is seeking a …
